Skip to main content
Premium Trial:

Request an Annual Quote

Halcyon's Days May Have Ended

The technology blog GigaOm reports that DNA sequencing startup Halcyon Molecular has shut down. According to GigaOm, "sources familiar with the Redwood City, Calif.-based company say that it ran out of money."

As previously reported by Daily Scan's sister publication In Sequence, the company was developing a method for sequencing DNA that relied on stretching out single-stranded DNA molecules on a substrate and reading labeled bases by transmission electron microscopy.

The technology promised reads of at least 150 kilobases and as long as 4 megabases, with the ability to sequence a human genome to more than 99.9999-percent consensus accuracy and completeness in less than 10 minutes, at a cost of less than $100.

The firm was founded in 2003 by brothers Michael and William Andregg and received venture capital funding from the Founders Fund, and, in 2009, it was awarded $1.29 million in funding from the National Human Genome Research Institute. Additionally, in 2009, it received just over $244,000 under the Qualifying Therapeutic Discovery Project Program, created by the US Patient Protection and Affordable Care Act.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.